FDA accepts resubmission of OTLK's BLA for ONS-5010; PDUFA date set for August 27, 2025

Outlook Therapeutics, Inc.

FDA acknowledged receipt of resubmission of BLA for ONS-5010 (bevacizumab-vikg).
FDA designated the BLA as a Class 2 review with a six-month review period.
PDUFA goal date for the BLA is August 27, 2025.

item 8.01

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-004606

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.